Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?
2026-07-20 18:10
•Adria Cimino •The Motley Fool
••• •• Axe Capital view
Eli Lilly’s $1,000+ Share Price Sparks Stock Split Talk
Eli Lilly’s rising stock price on US markets raises the question: will a stock split make shares more accessible and fuel further gains?
Eli Lilly's shares have surged past $1,000, largely thanks to their weight loss drug success and promising pipeline drugs like retatrutide. In the US, companies often split stocks to keep prices manageable and attract retail investors. Lilly hasn’t split since 1997, but at this price level, it could be on the cards. For South African investors, it’s worth watching because it could trigger renewed international interest and capital flows into related healthcare sectors on the JSE. Think about companies like Aspen or even broader pharma ETFs. That said, the rand’s USD/ZAR moves will remain key to translating any foreign gains here. A split doesn’t change fundamentals but does signal management’s confidence in growth ahead. If US inflation or interest rates turn sharply, all bets are off and Lilly could stall. this is just my opinion and not financial advice
Watch Eli Lilly for a potential split announcement, which could boost tech and healthcare links on the JSE due to increased foreign flows. Stay mindful of USD/ZAR fluctuations as the main channel for global pharma trends to impact local markets.
- LLY
- USD/ZAR
- Aspen
- US interest rate shocks that dent pharma valuations
- Rand weakness wiping out offshore gains
6/10
Eli Lilly's stock has surged above $1,000, driven primarily by its dominant position in the weight loss drug market. With the stock trading at these elevated levels, analysts speculate whether the company might announce a stock split to make shares more accessible to investors. While Lilly hasn't executed a stock split since 1997, a move could broaden its investor base and signal management confidence in future growth, particularly given recent launches like Foundayo and strong trial results for retatrutide.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Adria Cimino
Categories: Equities, Earnings, Healthcare
Tickers: LLY, JNJ
Sentiment: Positive - The company has experienced significant stock appreciation driven by blockbuster weight loss drug portfolio, recent product launches (Foundayo), and strong clinical trial results (retatrutide phase 3). The article suggests a potential stock split announcement could further boost investor accessibility and signal management confidence in continued growth. Mentioned only in a comparative context ('Johnson & Johnson vs. Eli Lilly') in the 'Read Next' section without substantive discussion of the company's performance or prospects in the main article.
Keywords: stock split, weight loss drugs, pharmaceutical, stock price, market accessibility, GLP-1 market, Foundayo, retatrutide
Insights:
- LLY: Positive: The company has experienced significant stock appreciation driven by blockbuster weight loss drug portfolio, recent product launches (Foundayo), and strong clinical trial results (retatrutide phase 3). The article suggests a potential stock split announcement could further boost investor accessibility and signal management confidence in continued growth.
- JNJ: Neutral: Mentioned only in a comparative context ('Johnson & Johnson vs. Eli Lilly') in the 'Read Next' section without substantive discussion of the company's performance or prospects in the main article.